Skip to content
‹ Back to IndustriesSciences

The Goals for Space Exploration for This Decade and Beyond

In this episode, Chris Blackerby and Charity Weeden speak with Ellen Stofan, Under Secretary of Science and Research at the Smithsonian, about the trajectory of space exploration in the current decade and beyond. The conversation covers the evolving roles of government agencies and private sector companies, as well as the importance of public engagement in advancing space science. Stofan draws on her extensive career at NASA and the Smithsonian to outline priorities and challenges facing the space community.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · International Space StationSpaceSustainabilityThe Expanse
Share

Key takeaways

01

Government and private sector collaboration is central to advancing space exploration goals this decade.

02

Public engagement and science communication are critical to sustaining support for space missions.

03

Ellen Stofan highlights the evolving priorities at NASA and the Smithsonian in shaping the future of space science.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The expanse of space, the wondrous and eerie world that very few individuals have experienced. In this episode, Chris Blackerby and Charity Weeden talk to Ellen Stofan, Under Secretary of Science and Research at the Smithsonian, about the future of space exploration in the government and private sectors, the public.

Stofan’s career in space was destined when she was four years old and watched a launch of the ATLAS-CENTAUR. Her father was an engineer on the rocket. However, the rocket exploded, and the vast mushroom cloud made four-year-old-Stofan remember the moment forever. The explosion was an unfortunate outcome, and it’s important to remember that a test flight that produces knowledge is not a failure.

She said that launches are one of her favorite parts of her job, but to this day, she gets nervous. “It’s an overwhelming feeling when the hardware you worked on is out in space,” chimed in the host, Blackerby. “When we launched our first satellite in March of last year, [it] was so emotional.”

Stofan became interested in geology and soon realized that geology and space go hand in hand. Stofan became Chief Scientist at Nasa, where her focus was getting Nasa Data into the hands of people worldwide to help combat climate change.

Today, Stofan believes that this decade will be vital in determining the future of space exploration. As private investments into the expanse become the norm, the government will be able to shift its focus to further investigation, like Mars. Determining and applying something like the Leeds Standards [sustainability-focused practices in the building industry] to space building and exploration is necessary to establishing space sustainability. Sustainability will be required, from how space crafts are disposed of to entering and exiting orbit. Since space is a global common, authority is undetermined. The public will play a vital role in ensuring that sustainable practices happen immediately.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

CB
Chris Blackerby

Partner, Government & Public Sector at EY

Chris Blackerby is a partner at EY focused on aerospace and government sectors, with a background spanning NASA and international space policy. He has held leadership roles including COO of the Asia-Pacific region for NASA and has worked on commercial space initiatives. Blackerby is a recognized voice on the intersection of government, private industry, and space exploration.

ES
Ellen Stofan

Under Secretary of Science and Research

Smithsonian Institution

Ellen Stofan is the Under Secretary of Science and Research at the Smithsonian Institution, overseeing its science research and museum units. She previously served as NASA's Chief Scientist from 2013 to 2016 and has had a distinguished career in planetary science. Stofan is a leading advocate for human and robotic space exploration.

CW
Charity Weeden

Vice President, Global Space Policy

Astroscale

Charity Weeden is a space policy expert with extensive experience in government and industry roles related to commercial space and satellite operations. She has held senior positions focused on space policy and regulatory affairs. Weeden is a frequent speaker on issues of space sustainability and international space governance.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512